Show simple item record

dc.contributor.authorGarcía Pinel, Beatriz
dc.contributor.authorPorras Alcalá, Cristina
dc.contributor.authorOrtega Rodríguez, Alicia
dc.contributor.authorSarabia, Francisco
dc.contributor.authorPrados Salazar, José Carlos 
dc.contributor.authorMelguizo Alonso, Consolación 
dc.contributor.authorLópez Romero, Juan Manuel
dc.date.accessioned2020-05-11T11:58:42Z
dc.date.available2020-05-11T11:58:42Z
dc.date.issued2019-04-19
dc.identifier.citationGarcía-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019). Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials, 9(4), 638.es_ES
dc.identifier.urihttp://hdl.handle.net/10481/61934
dc.description.abstractMany therapeutically active molecules are non-soluble in aqueous systems, chemically and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most promising colloidal carriers for bioactive organic molecules. Their current application in oncology has revolutionized cancer treatment by improving the antitumor activity of several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability, high loading capacity, ease of preparation, low production costs, and large-scale industrial production since they can be prepared from natural sources. Moreover, the association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical trials. This review summarizes the types of LBNPs that have been developed in recent years and the main results when applied in cancer treatment, including essential assays in patients.es_ES
dc.description.sponsorshipThis work was supported by Consejería de Salud de la Junta de Andalucía (project PI-0476-2016 and PI-0102-2017), by CICYT, Spain (project CTQ16-76311) and by FPU16/01716 (B. Garcia-Pinel) from Ministerio Ciencia, Innovación y Universidades.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectLipid-based nanoparticleses_ES
dc.subjectDrug releasees_ES
dc.subjectDrug resistancees_ES
dc.subjectClinical trials es_ES
dc.subjectCancer es_ES
dc.titleLipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatmentes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/nano9040638


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España